Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-2294 in Moderately to Severely Active Rheumatoid Arthritis
NCT07904754Phase 2Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2026
- Primary completion
- Jul 2029
01
Overview
A Phase 2 trial of ABBV-722 in rheumatoid arthritis (RA), sponsored by AbbVie Inc.. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
ABBV-722
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07904754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07904754.